Sun Pharma: This heavyweight stock will run on the basis of strong product portfolio, suggests buying brokerage; Check the goal

Buy on Sun Pharma: Corporate development has created opportunities to buy some quality stock amidst the uncertainty of the stock market. One of them is Sun Pharma in the stock pharma sector. Brokerage house Motilal Oswal has suggested buying the stock, which has risen more than 48 per cent in the past one year. Recently, Canadian firm Cipher Pharma entered into a revised distribution and supply agreement with Sun Pharma. This will give the company exclusive rights to sell and distribute in the US market. The brokerage firm says the company’s portfolio is strong and has performed better in the industry.

Sun Pharma: Target 1000 rupees

Brokerage firm Motilal Oswal has suggested buying Sun Pharma. The target has been set at one thousand rupees per share. The stock closed at Rs 902 on March 11. That way, investors can get a good return of about 11 percent on this bluechip stock. The performance of this stock has been good in the last one year. During this time, an increase of about 48 percent has been recorded.

Watch G Business dgmartpro.com Live TV here

What is the opinion of brokers

The brokerage firm says the recent distribution and supply agreement with the Canadian company will give the company exclusive rights in the US market. The attitude of the brokerage towards the company is positive. Behind this, the company says that the performance of the company has improved in its special portfolio. The company has better growth than the branded generic market industry in domestic and other emerging countries. At the same time, the company is also growing in the US generic market. Keeping in view the positive outlook of the company, Motilal Oswal suggested buying the stock with a target of Rs 1,000.

(Disclaimer: The investment advice here is provided by the brokerage house. This is not a G-Business opinion. Please consult your advisor before investing.)